Your session is about to expire
← Back to Search
Steroid
LPCN 1144 for Non-alcoholic Fatty Liver Disease
Phase 2
Waitlist Available
Research Sponsored by Lipocine Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 36
Awards & highlights
Study Summary
This study is evaluating whether LPCN 1144 is safe and tolerable in adults with NASH.
Eligible Conditions
- Non-alcoholic Fatty Liver Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to week 36
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 36
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Measure the effect of LPCN 1144 on hematology panels
Measure the effect of LPCN 1144 on liver injury markers
Measure the effect of LPCN 1144 on serum lipid panels
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Treatment AExperimental Treatment1 Intervention
LPCN 1144
Find a Location
Who is running the clinical trial?
Lipocine Inc.Lead Sponsor
6 Previous Clinical Trials
734 Total Patients Enrolled
1 Trials studying Non-alcoholic Fatty Liver Disease
56 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger